New Releases from NCBI BookshelfSemaglutide (Wegovy): Therapeutic area: Weight management: Reimbursement Review [Internet].Semaglutide (Wegovy): Therapeutic area: Weight management: Reimbursement Review [Internet].
Post Content
Uncategorized
Uncategorized
New Releases from NCBI BookshelfTalazoparib (Talzenna): Indication: Talazoparib in combination with enzalutamide for the treatment of adult patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: Reimbursement Recommendation [Internet].Talazoparib (Talzenna): Indication: Talazoparib in combination with enzalutamide for the treatment of adult patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Talzenna in combination with enzalutamide should be reimbursed by public drug plans for the
Uncategorized
New Releases from NCBI BookshelfPembrolizumab (Keytruda): Indication: Treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy: Reimbursement Recommendation [Internet].Pembrolizumab (Keytruda): Indication: Treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Keytruda in combination with chemoradiotherapy be reimbursed by public drug plans for the treatment
Uncategorized
New Releases from NCBI BookshelfQuetiapine for Bipolar Disorder: Drugs [Internet].Quetiapine for Bipolar Disorder: Drugs [Internet].
Quetiapine, among other antipsychotics, could be used as a first-line treatment option for the management of bipolar disorder in adults.
Uncategorized
New Releases from NCBI BookshelfNivolumab Plus Ipilimumab (Opdivo Plus Yervoy): Indication: For the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer: Reimbursement Recommendation [Internet].Nivolumab Plus Ipilimumab (Opdivo Plus Yervoy): Indication: For the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Opdivo in combination with Yervoy be reimbursed by public drug plans for the first-line
